MDT Stock Signals 25% Upside After Strong Q4 Results

Medtronic NYSE: MDT the main thing as it approaches the middle of the year is that the winds are not the results as feared. Rising costs, margin compression, and general uncertainty related to macroeconomic headwinds were reflected in the company's June 3 earnings results, but the results were solid in nature and expected to remain so.

The impact on stock prices will increase, as the market is oversold and ripe for another rally. The only question is how high the stock price can go, and signs suggest that a 25% increase is easy.

Medtronic is trading within a long-term range, with key resistance near $95. The $95 level is more than 25% above the key support level, where MDT has been trading since early June. While lower rates remain a possibility, the response to MDT's Q4 2026 earnings report suggests that a bottom is in place, and a recovery has begun.

Analysts and Institutions Show Confidence in MDT Capital Return

Analyst trends also indicate that a 25% increase in stock price is an easy target. The trends leading up to the release have been mixed, with many lowering the price target, but the data suggests that they are simply adjusting the target, rather than making major price changes. The result is that although the consensus has fallen further, it still predicts a strong 20% ​​upside and the potential for new highs. The likely outcome is that Q4 results will spark renewed confidence in the company's ability to generate cash flow, which is important in this context.

Medtronic is a well-known dividend grower on the verge of being crowned the Dividend King. Q4 results included a 49 consecutive increase in distributions, worth about 1.4% to investors, putting it in the position of being included in more indexes and improved institutional ownership, which is a driver of share prices. As it is, the yield is around 3.5%, with low trading grade shares and only 50% of earnings. The likely result is that Medtronic supports growth over time, both in business and budget, although the pace may not be strong.

Institutions show confidence in the profitability and intrinsic value of the company, which owns more than 80% of the stock. Index-related holdings are high, but the ownership base is broad, and the group is accumulating. MarketBeat data reveals six consecutive quarters of bullish behavior, including Q2 2026 to date. A possible consequence of this vector is that procurement activity continues to accumulate as institutions take advantage of the value-to-yield combination. Trading at 13X this year's earnings outlook, the stock is cheap relative to the S&P 500, offering nearly four times the yield of the S&P 500 Index Tracking ETF. NYSEARCA: CHECKand offers low-beta exposure to real-time AI and the Internet of Things.

Medtronic's portfolio stands tall

Medtronic had a good quarter with revenue up 9.9% to more than $9.8 billion. The top line came in 200 basis points (bps) better than expected, based on strength across all segments. Cardiovascular led with a 10.1% gain, driven by Cardiac Ablation Solutions' 78% increase, while diabetes care grew by 8.1%, medical surgery by 5.1%, and neuroscience by 3%.

Margin news was mixed, but the market feared the worst, as evidenced by the decline in reviews leading up to the release. Diluted adjusted earnings fell 4.3% to $1.55, offset by an outperformance of more than 65 points and sufficient cash flow and benefits to support balance sheet health.

Direction is another factor that points to a strong increase in the stock price. The company's initial guidance for fiscal 2027 includes organic revenue growth of 7% and faster earnings growth. The bad news is that both targets were slightly below the consensus forecast, but, again, the market was very scared.

This year's catalysts include MiniMedNASDAQ: MMED spin-off. The first IPO has been completed, and the final step is expected later this year. In it, Medtronic will enable existing shareholders to exchange MMED shares, effectively canceling one for another. The result will be the distribution of the remaining 80% of MMED and the reduction of MDT shares. This move is expected to drive higher profits while allowing more focused companies to execute their strategies more effectively.

Medtronic's risks remain unchanged. While traditional recall and competitive risk are ubiquitous in the industry, it also faces tax threats and the growing need for cyber security. AI has changed the game in cybersecurity, introducing new challenges such as data poisoning. Inaccurate, disjointed, and otherwise harmful data negatively impacts AI models and agent-influenced health outcomes.

Before you consider Medtronic, you'll want to hear this.

MarketBeat tracks Wall Street's top and most effective research analysts and the stocks they recommend to their clients every day. MarketBeat identified five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Medtronic wasn't on the list.

Although Medtronic currently has an Average Buy rating among analysts, top analysts believe these five stocks are the best.

View Five Stocks Here

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and social markets before investing.

Get This Free Report

Do you like this article? Share with your colleagues.

The link is copied to the clipboard.